COVID-19 vaccine

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Retrieved on: 
Tuesday, December 26, 2023
BioNTech, CVAC, Federal court, Patent, Federal Patent Court (Germany), Messenger, COVID-19, CureVac, Bird, Vaccine, Justice, Sąd rejonowy, COVID-19 vaccine, EP 1, Intellectual property, LLP

CureVac will appeal before the German Federal Court of Justice.

Key Points: 
  • CureVac will appeal before the German Federal Court of Justice.
  • The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights.
  • “We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year.
  • The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®.

Pfizer Provides Full-Year 2024 Guidance

Retrieved on: 
Wednesday, December 13, 2023
Professional Services, Health, Finance, Banking, Pharmaceutical, Biotechnology, Research, Safety, Acquisition, Pediatrics, Overview, Federation, Annual report, Risk, COVID-19 vaccine, Clinical trial, Intellectual property, EPS, Formula, Vaccine, Messenger, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Omicron, Global Economic Symposium, GAAP, Analysis, BioNTech, MD, EST, Public, BNT162, Dive (Belgian band), Financial condition report, Publication, Result, Originality, Security (finance), Pharmaceutical industry, Risk management, Pfizer, Seagen

Financial guidance for Adjusted(5) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.

Key Points: 
  • Financial guidance for Adjusted(5) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.
  • As announced on December 12, 2023, Pfizer and Seagen have received all required regulatory approvals for the closing of the acquisition.
  • Pfizer expects to complete the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
  • Financial guidance for full-year 2024 reflects the following:
    Guidance for Adjusted(5) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.75 billion shares, and assumes no share repurchases in 2024.

EU medicines agencies reflect on lessons learned from COVID-19

Retrieved on: 
Monday, December 18, 2023
Safety, COVID-19 vaccine, HMA, EMA, Agency, European, Collaboration, Vaccine, COVID-19, Mass vaccination, Therapy, Communication, Review, Workload, Network, Public, Pharmaceutical industry, Medical device

Additionally, the European Union (EU) safety monitoring and risk management system was strengthened to collect and monitor the high volume of data from the mass vaccination campaigns.

Key Points: 
  • Additionally, the European Union (EU) safety monitoring and risk management system was strengthened to collect and monitor the high volume of data from the mass vaccination campaigns.
  • Throughout the COVID-19 crisis, the EMRN also ensured that medicines for other diseases affecting Europeans continued to be evaluated and supervised without delays.
  • In addition, the ongoing review of the EU pharmaceutical legislation will also provide a vehicle to bring about other changes to the EU regulatory toolbox.
  • The recommendations will also be considered in future updates of the European Medicines Agencies Network strategy.

Major new vaccines initiative aims to fight deadly airborne infections

Retrieved on: 
Monday, December 18, 2023
Novo Nordisk Foundation, SSI, Research, Senior, Nasal spray, Disease, Statens Serum Institut, History, Faculty, University of Copenhagen, Immunology, Death, Vaccine, Science, GAS, Influenza, Medicine, University, Infection, Human, Partnership, DKK, Interior, Streptococcus, COVID-19 vaccine, Respiratory system, Microbiology, COVID-19, Knowledge, Life, Tuberculosis, Public, TB, Pharmaceutical industry, Management, Immunity, NIVI, Health

The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.

Key Points: 
  • The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.
  • Developed in partnership with the University of Copenhagen, it is the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself.
  • "The development of the Covid-19 vaccines demonstrated the extraordinary possibilities when interdisciplinary vaccine research and development are prioritised," says Krogsgaard Thomsen.
  • "We hope that NIVI's work can help prepare us for the next pandemic or even help consign airborne epidemics to history."

Major new vaccines initiative aims to fight deadly airborne infections

Retrieved on: 
Monday, December 18, 2023
Novo Nordisk Foundation, SSI, Research, Senior, Nasal spray, Disease, Statens Serum Institut, History, Faculty, University of Copenhagen, Immunology, Death, Vaccine, Science, GAS, Influenza, Medicine, University, Infection, Human, Partnership, DKK, Interior, Streptococcus, COVID-19 vaccine, Respiratory system, Microbiology, COVID-19, Knowledge, Life, Tuberculosis, Public, TB, Pharmaceutical industry, Management, Immunity, NIVI, Health

The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.

Key Points: 
  • The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.
  • Developed in partnership with the University of Copenhagen, it is the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself.
  • "The development of the Covid-19 vaccines demonstrated the extraordinary possibilities when interdisciplinary vaccine research and development are prioritised," says Krogsgaard Thomsen.
  • "We hope that NIVI's work can help prepare us for the next pandemic or even help consign airborne epidemics to history."

Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver

Retrieved on: 
Tuesday, December 5, 2023
World Trade Organization, Creativity, IP, UN, Commerce, Patient, Council, Defense, Therapy, Conference, World Intellectual Property Organization, Patent, COVID-19 vaccine, Innovation, COVID-19, Letter, Government, Pharmaceutical industry

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Yesterday, the Council for Innovation Promotion (C4IP) and nearly 50 former government officials and intellectual property experts sent a letter to President Biden urging his administration to oppose the World Trade Organization's proposed IP waiver for Covid-19 therapeutics and diagnostics.

Key Points: 
  • WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Yesterday, the Council for Innovation Promotion (C4IP) and nearly 50 former government officials and intellectual property experts sent a letter to President Biden urging his administration to oppose the World Trade Organization's proposed IP waiver for Covid-19 therapeutics and diagnostics.
  • "The Council for Innovation Promotion is honored to lead this distinguished group in advocating for the preservation of global IP rights," said Frank Cullen, C4IP executive director.
  • "IP drives creativity and innovation worldwide, and the bipartisan solidarity of this group sends a clear message about the importance of maintaining these safeguards.
  • We hope the Biden administration strongly considers these experts' voices when evaluating the WTO's proposed IP waiver."

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Monday, October 30, 2023
Bone marrow, CAR, Immunodeficiency, Fred Hutchinson Cancer Research Center, Biotechnology, Hope, COVID-19 vaccine, City, Pfizer, COVID-19, Cancer, Messenger, GeoVax, University, Atrium Health Wake Forest Baptist, Infection, Safety, Patient, Vaccine, Moderna

ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients. In addition to study enrollments completed at the City of Hope Medical Center (Duarte, California), the trial will be initiating enrollment of eligible patients at Wake Forest Baptist Medical Center (Winston Salem, North Carolina), the University of Massachusetts Medical Center (Worcester, Massachusetts), and Fred Hutchinson Cancer Research Center (Seattle, Washington).

Key Points: 
  • ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients.
  • Such patients often have difficulty mounting an adequate protective antibody response after receiving currently available COVID-19 vaccines.
  • In the U.S., there are approximately 15 million individuals who, as a result of their compromised immune systems, often do not adequately respond to the current authorized vaccines.
  • These data support the progression of the Phase 2 clinical study, which includes a direct comparison to currently approved mRNA vaccines.

Global mRNA Vaccine Market Research Report 2023: On-going Clinical Trials, Drug Pipeline, Mergers & Acquisitions, & Product Launches - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023
Health, Pharmaceutical, Perelman School of Medicine at the University of Pennsylvania, Pharmacology, Infection, ClinicalTrials.gov, Vaccine, SARS-CoV-2, RNA, Antigen, Biotechnology, Mortality, Penn, Mutation, Safety, HIV, Cytokine, University, TSA, Research, Cell, Protein, Arcturus Therapeutics, Application, Death, COVID-19 vaccine, Pfizer, Growth, Genome, Vaccination, Lipid, COVID-19, Risk, Viral, Immunity, TAA, Competition, Messenger, DSM-IV codes, MRNA vaccine, Cancer, Investment, Therapy, Patient, Toxicity, Zika virus, Rabies virus, DNA

Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.

Key Points: 
  • Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.
  • The global mRNA vaccine market experiences growth driven by the increasing occurrence of cancer, genetic anomalies, and viral infections.
  • This has prompted numerous biotechnology and pharmaceutical companies, along with academic and research institutions, to engage in research, development, and clinical trials for various mRNA vaccines.
  • This, in turn, creates promising prospects for the global mRNA vaccine market during the forecast period.

Henry Schein to Webcast Third Quarter 2023 Conference Call and Provide an Update on Its Full-Year 2023 Guidance on Monday, November 13, 2023 at 10:00 a.m. ET

Retrieved on: 
Thursday, November 2, 2023
Medical Devices, Health, Dental, Practice Management, Medical Supplies, Sale, Affordable Care Act, Security (finance), Coronavirus, Terrorism, Health information management, Form 10-K, Care Act 2014, Intellectual property, PPE, Senior, COVID-19 vaccine, Epidemic, COVID-19, Disease, Henry Schein, Risk factor, Privacy, Pandemic, Public, Annual report, Collection, Failure, Pharmaceutical industry

Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.

Key Points: 
  • Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.
  • A replay will be available on the Henry Schein website following the presentation.
  • The Company expects to file its Form 10 for the quarterly period ended September 30, 2023, before the end of November 2023.
  • We undertake no duty and have no obligation to update forward-looking statements except as required by law.

GHLF Announces New Vaccine Podcast, "Informed Immunity: A Guide to Vaccines for the Chronic Illness Community" Plus More Credible Resources for Patients and Policymakers Alike

Retrieved on: 
Tuesday, October 31, 2023
Pharmaceutical, General Health, Health, COVID-19, Media, Infectious Diseases, Communications, Social Activism, Medical Affairs Bureau, RSV, Education, Vaccine, Policy, MD, Immunity, Research, COVID-19 vaccine, Doctor of Pharmacy, Patient, Pharmaceutical industry

"Informed Immunity: A Guide to Vaccines for the Chronic Illness Community," is part of GHLF’s Wellness Evolution podcast group, taking a deep dive into the world of vaccines, tackling crucial topics that impact community health — respiratory infectious diseases, vaccine advocacy, and more.

Key Points: 
  • "Informed Immunity: A Guide to Vaccines for the Chronic Illness Community," is part of GHLF’s Wellness Evolution podcast group, taking a deep dive into the world of vaccines, tackling crucial topics that impact community health — respiratory infectious diseases, vaccine advocacy, and more.
  • "In today's health care landscape, we often witness a system that is fractured and complex, leaving patients to navigate endless hurdles," said Robert Popovian, PharmD, Chief Science Policy Offer at GHLF.
  • These words underscore the Global Healthy Living Foundation’s mission to provide the public with easily accessible, evidence-based vaccine information.
  • This comprehensive resource will serve as a hub for patients and policymakers alike, fostering collaboration and informed decision-making.